Avadel Pharmaceuticals (AVDL) Quarterly EPS earnings growth

Avadel Pharma - graphic logo of issuer AVDL

Avadel Pharmaceuticals (AVDL) generates revenue through the sale of innovative treatments for narcolepsy. Quarterly net income per share growth rates visualize the development dynamics, where the 100.40 level indicates the parameter's status. The success of the drug Lumryz and expansion into pediatrics serve as the primary drivers. Due to its product cycle, the business ignores macroeconomic trends, remaining a reliable defensive asset during recessions.

Avadel Pharmaceuticals plc (AVDL) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 02/28/2026

AVDL (Avadel Pharmaceuticals plc): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Fundamental valuation:Avadel Pharmaceuticals PLC - AVDL
Flagship merchandise of avadel.com

This indicator measures the quarterly change in net income per share, reflecting the pace of operational efficiency. Analyzing quarterly earnings per share growth allows for the identification of the true profitability trend without market noise. The metric captures the growth rate of capital available to shareholders after all expenses are deducted. For Avadel Pharmaceuticals (AVDL), this figure depends directly on the commercial success of its narcolepsy drug. Patent protection and lobbying create a foundation for stable EPS growth, despite the stringent restrictions of the REMS program.

Competitor analysis

ALKS (alkermes.com) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months atai Life Sciences Corp (ATAI)|GHRS (ghres.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Mind Medicine (MNMD)|Quarterly EPS earnings growth CMPS|LBRX (LB Pharmaceuticals, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months brightmindsbio.com DRUG|Vanda Pharmaceuticals (VNDA) - Earnings per share growth in annualized terms for the last twelve months|Cybin - Quarterly EPS earnings growth|ANRO - Quarterly EPS earnings growth|NRx Pharmaceuticals, Inc. (NRXP) - Year-over-year earnings per share growth for the last twelve months|CING - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Silo Pharma, Inc.|chinapharmaholdings.com (CPHI) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth CMND|Psyence Biomedical Ltd. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months SciSparc Ltd SPRC|Seelos Therapeutics Inc. (SEEL) - Earnings per share growth in annualized terms for the last twelve months|VRPX: Year-over-year net earnings per share growth for the last 12 months|KRTX - Quarterly EPS earnings growth